Ada terobosan terbaru dalam kanker paru-paru non-sel kecil. Semacam imunisasi yang dapat mengobati kanker paru-paru non-sel kecil (NSCLC) telah mengalami persetujuan klinis stadium 3 dan memiliki dampak terapeutik yang besar pada penyakit paru-paru bukan sel kecil. Sekarang ini dapat diakses di beberapa negara.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung vaksin kanker dapat meningkatkan tingkat kelangsungan hidup pasien dengan NSCLC stadium kambuh dan lanjutan (stadium IIIB/IV).
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Setelah kerangka insusceptible menghasilkan antibodi eksplisit terhadap Antigen, dapat membuat antibodi melawan keunikan antigen utama, yang dapat mengontrol kerangka resisten dari dalam. Setelah diimunisasi terhadap pertumbuhan ganas paru-paru ini imunisasi, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumor antigen.
Telah dibuktikan secara klinis bahwa penyakit paru-paru imunisasi sangat bertahan dan memiliki kinerja yang lebih baik. Banyak gejala dasar yang terjadi hanya secara lokal (tempat infus) dan umumnya lembut dan panjangnya singkat. Terlepas dari apakah antibodi diberikan kepada pasien setelah kondisinya hancur, daya tahan umum mereka meningkat.
Saat ini, imunisasi pertumbuhan ganas paru semacam ini tidak dipromosikan di India.
